drugset / Trial / NCT03721744
A Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase II/III Randomized, Open-Label Clinical Study of GB201 in Combination with Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Metastatic Pancreatic Cancer Following Chemotherapy Failure
Timeline
- Start
- 2018-10-25
- Primary completion
- 2025-03
- Completion
- 2025-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | 600 mg/m2 | Intravenous |
| Subject | Napabucasin | Small molecule | — | Oral |
| Subject | Paclitaxel | Small molecule | 80 mg/m2 | Intravenous |